tubulin folding cofactor A pseudogene 2Genealiases: []
Q-omics provides the consensus-scored TBCAP2 profile across patient tissues and cancer cell-line models. TBCAP2 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TBCAP2 is differentially expressed in 3, with the highest sampling consensus in KICH. Additionally, TBCAP2 RNA expression shows 9,962 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRP, KICH, and HNSC as cancer lineages where TBCAP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBCAP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBCAP2 survival associations across molecular data types. TBCAP2 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBCAP2 RNA expression–survival associations across cancer types. High TBCAP2 expression shows unfavorable associations in LIHC and COAD, but favorable associations in KIRP, LUAD, LUSC and ESCA. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .009). Together, the overview and detailed table identify KIRP as the clearest survival context for TBCAP2 RNA expression.
This table summarizes TBCAP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TBCAP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBCAP2 shows lower tumor expression in KICH and higher tumor expression in LUSC and COAD. The KICH box plot shows higher TBCAP2 RNA expression in normal versus tumor tissue (log2 FC = −0.110, t-test p = .002).
This table shows molecular features associated with TBCAP2 in patient tissues and cancer cell lines. In patient samples, TBCAP2 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
